Presentation is loading. Please wait.

Presentation is loading. Please wait.

Supplementary Figures&Legends. Figure1. Subcutaneous xenograft tumor models of the control group.

Published bySophia Booth Modified over 9 years ago

Similar presentations

Presentation on theme: "Supplementary Figures&Legends. Figure1. Subcutaneous xenograft tumor models of the control group."— Presentation transcript:

1 Supplementary Figures&Legends

2 Figure1. Subcutaneous xenograft tumor models of the control group.

3 Figure1. One of the subcutaneous xenograft tumor models in the control group.As shown in the picture, the width of the tumor is 10mm, and the tumor volume is about 1300mm 3, which is the mean volume of tumors in control group.

4 Figure3. Subcutaneous xenograft tumor models treated with 10mg S(MeO)TLC. The tumor volume of mice in this group is varies, but the mean volume is lower than the control group significantly(P ＜ 0.05).

5 Figure4. Subcutaneous xenograft tumor models treated with 20mg S(MeO)TLC. The average tumor volume of mice in this group is significantly lower than the control group and the 10mg group(P ＜ 0.05). In addition, it is noted that there was necrosis on the tumor surfaces of some treated mice, especially in the 20 mg kg–1 S(MeO)TLC treatment group.

Download ppt "Supplementary Figures&Legends. Figure1. Subcutaneous xenograft tumor models of the control group."

Similar presentations

P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.

P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.
Herceptin + 17-AAG Combination BT-474 Tumors

Herceptin + 17-AAG Combination BT-474 Tumors
Ki67 SPATIAL DISTRIBUTION Ki67 PROLIFERATION REOXYGENATION 48 hours SUPPLEMENTARY FIGURES S1ABC Figure S1. Reoxygenation and Repopulation at 48 hours in.

Ki67 SPATIAL DISTRIBUTION Ki67 PROLIFERATION REOXYGENATION 48 hours SUPPLEMENTARY FIGURES S1ABC Figure S1. Reoxygenation and Repopulation at 48 hours in.
Complete the following metric conversions using the correct number of significant figures a. 28.0 cm to m   b. 1000. m to km c. 9.28 cm to mm d. 10.68.

Complete the following metric conversions using the correct number of significant figures a cm to m   b m to km c cm to mm d
Supplementary Figure 1. The effect of 17-DMAG on the growth of lung cancer cells with Met amplification Tumor cells were continuously treated with increasing.

Supplementary Figure 1. The effect of 17-DMAG on the growth of lung cancer cells with Met amplification Tumor cells were continuously treated with increasing.
Supplemental Data. Supplemental Data contains three figures. Supplemental data Figure 1 shows an example of the HPLC technique used to measure BH4:BH2.

Supplemental Data. Supplemental Data contains three figures. Supplemental data Figure 1 shows an example of the HPLC technique used to measure BH4:BH2.
CohortTreatment groups DoseMode of administration Number of animals DT01 + OXA + 5-FU sacrificed day 22 Vehicle (NaCl + glucose) 0.9% 5% IP 9 OXA 5-FU.

CohortTreatment groups DoseMode of administration Number of animals DT01 + OXA + 5-FU sacrificed day 22 Vehicle (NaCl + glucose) 0.9% 5% IP 9 OXA 5-FU.
The reading is 7.38 mm. The reading is 7.72 mm.

The reading is 7.38 mm. The reading is 7.72 mm.
Supplementary information Figure S1 Parental Mock ANXA1-V5 GAPDH MCF7-EV MCF7-V5 4 5 ANXA1 ANXA1-V5 Tubulin MCF7-parental MCF7-EV MCF7-V5 1 2 3 A B C ANXA1.

Supplementary information Figure S1 Parental Mock ANXA1-V5 GAPDH MCF7-EV MCF7-V5 4 5 ANXA1 ANXA1-V5 Tubulin MCF7-parental MCF7-EV MCF7-V A B C ANXA1.
Convert into scientific notation:

Convert into scientific notation:
Fig. 1. Effects of letrozole (Let; 10 μg/day) and tamoxifen (Tam; 100 μg/day) and their combined or alternating treatment on the growth of MCF-7Ca breast.

Fig. 1. Effects of letrozole (Let; 10 μg/day) and tamoxifen (Tam; 100 μg/day) and their combined or alternating treatment on the growth of MCF-7Ca breast.
Figure 1. Herbacetin binds to AKT1/2 and suppresses each respective kinase activity. The effect of herbacetin on (A) PI3K/AKT and (B) MAPK signaling pathway.

Figure 1. Herbacetin binds to AKT1/2 and suppresses each respective kinase activity. The effect of herbacetin on (A) PI3K/AKT and (B) MAPK signaling pathway.
Drug concentration (μM)

Drug concentration (μM)
Figure 3. Sensitivity of the gastric carcinoma cell line N87 for trastuzumab in comparison with the breast cancer cell line SKBR-3. (A) Dose–response curves.

Figure 3. Sensitivity of the gastric carcinoma cell line N87 for trastuzumab in comparison with the breast cancer cell line SKBR-3. (A) Dose–response curves.
Figure 1. Herbacetin binds to AKT1/2 and suppresses each respective kinase activity. The effect of herbacetin on (A) PI3K/AKT and (B) MAPK signaling pathway.

Figure 1. Herbacetin binds to AKT1/2 and suppresses each respective kinase activity. The effect of herbacetin on (A) PI3K/AKT and (B) MAPK signaling pathway.
SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models. SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models.

SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models. SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models.
Inhibition of CR HCT-116 (A and B) or CR HT-29 cells (B) xenografts in EPA and/or FuOx-treated SCID mice. Inhibition of CR HCT-116 (A and B) or CR HT-29.

Inhibition of CR HCT-116 (A and B) or CR HT-29 cells (B) xenografts in EPA and/or FuOx-treated SCID mice. Inhibition of CR HCT-116 (A and B) or CR HT-29.
Median Tumor Development Time

Median Tumor Development Time
Cyclooxygenase Regulates Angiogenesis Induced by Colon Cancer Cells

Cyclooxygenase Regulates Angiogenesis Induced by Colon Cancer Cells
Supplementary Figure S13

Supplementary Figure S13

Similar presentations

Ads by Google